Viral Vector & Plasmid DNA Manufacturing Market Size - Global Industry, Share, Analysis, Trends and Forecast 2024 - 2032

CHAPTER 1. Industry Overview of Viral Vector & Plasmid DNA Manufacturing Market

1.1. Definition and Scope

1.1.1. Definition of Viral Vector & Plasmid DNA Manufacturing

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Viral Vector & Plasmid DNA Manufacturing Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Viral Vector & Plasmid DNA Manufacturing Market By Vector Type

1.2.3. Viral Vector & Plasmid DNA Manufacturing Market By Workflow

1.2.4. Viral Vector & Plasmid DNA Manufacturing Market By Application

1.2.5. Viral Vector & Plasmid DNA Manufacturing Market By Disease

1.2.6. Viral Vector & Plasmid DNA Manufacturing Market By End Use

1.2.7. Viral Vector & Plasmid DNA Manufacturing Market By Region

CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.1.3. Driver 3

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.2.3. Restraint 3

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.3.3. Opportunity 3

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Viral Vector & Plasmid DNA Manufacturing Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Viral Vector & Plasmid DNA Manufacturing Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Cost Structure Analysis

3.8.1. Price Trend of Key Raw Materials

3.8.2. Raw Material Suppliers

3.8.3. Proportion of Manufacturing Cost Structure

3.8.3.1. Raw Material

3.8.3.2. Labor Cost

3.8.3.3. Manufacturing Expense

3.9. Regulatory Compliance

3.10. Competitive Landscape, 2023

3.10.1. Player Positioning Analysis

3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Manufacturing Plant Analysis

4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2023

4.2. R&D Status of Major Manufacturers in 2023

CHAPTER 5. Viral Vector & Plasmid DNA Manufacturing Market By Vector Type

5.1. Introduction

5.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Vector Type

5.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Vector Type, 2020-2032

5.2.2. Viral Vectors

5.2.2.1. Viral Vectors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.2.2. Adenovirus

5.2.2.2.1. Adenovirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.2.3. Retrovirus

5.2.2.3.1. Retrovirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.2.4. Adeno-Associated Virus (AAV)

5.2.2.4.1. Adeno-Associated Virus (AAV) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.2.5. Lentivirus

5.2.2.5.1. Lentivirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.2.6. Others

5.2.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.3. Plasmid DNA

5.2.3.1. Plasmid DNA Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 6. Viral Vector & Plasmid DNA Manufacturing Market By Workflow

6.1. Introduction

6.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Workflow

6.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Workflow, 2020-2032

6.2.2. Upstream Manufacturing

6.2.2.1. Upstream Manufacturing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.2.2. Vector Amplification & Expansion

6.2.2.2.1. Vector Amplification & Expansion Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.2.3. Vector Recovery/Harvesting

6.2.2.3.1. Vector Recovery/Harvesting Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3. Downstream Manufacturing

6.2.3.1. Downstream Manufacturing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.2. Purification

6.2.3.2.1. Purification Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.3. Fill Finish

6.2.3.3.1. Fill Finish Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 7. Viral Vector & Plasmid DNA Manufacturing Market By Application

7.1. Introduction

7.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Application

7.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Application, 2020-2032

7.2.2. Antisense & RNAi Therapy

7.2.2.1. Antisense & RNAi Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

7.2.3. Gene Therapy

7.2.3.1. Gene Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

7.2.4. Cell Therapy

7.2.4.1. Cell Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

7.2.5. Vaccinology

7.2.5.1. Vaccinology Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

7.2.6. Research Applications

7.2.6.1. Research Applications Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 8. Viral Vector & Plasmid DNA Manufacturing Market By Disease

8.1. Introduction

8.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Disease

8.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Disease, 2020-2032

8.2.2. Infectious Disease

8.2.2.1. Infectious Disease Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

8.2.3. Genetic Disorders

8.2.3.1. Genetic Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

8.2.4. Cancer

8.2.4.1. Cancer Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

8.2.5. Others

8.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 9. Viral Vector & Plasmid DNA Manufacturing Market By End Use

9.1. Introduction

9.2. Viral Vector & Plasmid DNA Manufacturing Revenue By End Use

9.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By End Use, 2020-2032

9.2.2. Pharmaceutical and Biopharmaceutical Companies

9.2.2.1. Pharmaceutical and Biopharmaceutical Companies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

9.2.3. Research Institutes

9.2.3.1. Research Institutes Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 10. North America Viral Vector & Plasmid DNA Manufacturing Market By Country 

10.1. North America Viral Vector & Plasmid DNA Manufacturing Market Overview

10.2. U.S.

10.2.1. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

10.2.2. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

10.2.3. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

10.2.4. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

10.2.5. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

10.3. Canada

10.3.1. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

10.3.2. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

10.3.3. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

10.3.4. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

10.3.5. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

10.4. North America PEST Analysis

CHAPTER 11. Europe Viral Vector & Plasmid DNA Manufacturing Market By Country

11.1. Europe Viral Vector & Plasmid DNA Manufacturing Market Overview

11.2. U.K.

11.2.1. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

11.2.2. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

11.2.3. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

11.2.4. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

11.2.5. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

11.3. Germany

11.3.1. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

11.3.2. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

11.3.3. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

11.3.4. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

11.3.5. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

11.4. France

11.4.1. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

11.4.2. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

11.4.3. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

11.4.4. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

11.4.5. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

11.5. Spain

11.5.1. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

11.5.2. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

11.5.3. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

11.5.4. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

11.5.5. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

11.6. Rest of Europe

11.6.1. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

11.6.2. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

11.6.3. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

11.6.4. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

11.6.5. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

11.7. Europe PEST Analysis

CHAPTER 12. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market By Country

12.1. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Overview

12.2. China

12.2.1. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.2.2. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.2.3. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.2.4. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.2.5. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.3. Japan

12.3.1. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.3.2. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.3.3. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.3.4. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.3.5. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.4. India

12.4.1. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.4.2. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.4.3. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.4.4. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.4.5. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.5. Australia

12.5.1. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.5.2. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.5.3. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.5.4. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.5.5. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.6. South Korea

12.6.1. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.6.2. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.6.3. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.6.4. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.6.5. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.7. Rest of Asia-Pacific

12.7.1. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

12.7.2. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

12.7.3. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

12.7.4. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

12.7.5. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

12.8. Asia Pacific PEST Analysis

CHAPTER 13. Latin America Viral Vector & Plasmid DNA Manufacturing Market By Country

13.1. Latin America Viral Vector & Plasmid DNA Manufacturing Market Overview

13.2. Brazil

13.2.1. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

13.2.2. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

13.2.3. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

13.2.4. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

13.2.5. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

13.3. Mexico

13.3.1. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

13.3.2. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

13.3.3. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

13.3.4. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

13.3.5. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

13.4. Rest of Latin America

13.4.1. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

13.4.2. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

13.4.3. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

13.4.4. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

13.4.5. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

13.5. Latin America PEST Analysis

CHAPTER 14. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market By Country 

14.1. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Overview

14.2. GCC

14.2.1. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

14.2.2. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

14.2.3. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

14.2.4. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

14.2.5. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

14.3. South Africa

14.3.1. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

14.3.2. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

14.3.3. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

14.3.4. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

14.3.5. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

14.4. Rest of Middle East & Africa

14.4.1. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032

14.4.2. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032

14.4.3. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032

14.4.4. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032

14.4.5. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032

14.5. Middle East & Africa PEST Analysis

CHAPTER 15. Player Analysis Of Viral Vector & Plasmid DNA Manufacturing Market

15.1. Viral Vector & Plasmid DNA Manufacturing Market Company Share Analysis

15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

15.2.2. New Product Launches and Product Enhancements

15.2.3. Mergers And Acquisition In Global Viral Vector & Plasmid DNA Manufacturing Market

15.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 16. Company Profile

16.1. Waisman Biomanufacturing

16.1.1. Company Snapshot

16.1.2. Business Overview

16.1.3. Financial Overview

16.1.3.1. Revenue (USD Billion), 2023

16.1.3.2. Waisman Biomanufacturing 2023 Viral Vector & Plasmid DNA Manufacturing Business Regional Distribution

16.1.4. Product /Service and Specification

16.1.5. Recent Developments & Business Strategy

16.2. Merck KGaA

16.3. RegenxBio, Inc.

16.4. Thermo Fisher Scientific

16.5. Catalent Inc.

16.6. Lonza Group AG

16.7. RegenxBio, Inc.

16.8. Cobra Biologics

16.9. Audentes Therapeutics

16.10. Takara Bio Inc.

16.11. BioNTech IMFS GmbH

16.12. FUJIFILM Diosynth Biotechnologies

16.13. Virovek Incorporation

16.14. SIRION Biotech GmbH

16.15. Genezen laboratories

16.16. Miltenyi Biotec GmbH